Phase 4 N=121 Glaucoma Biomarkers
Glaucoma · Healthy
Primary: Variation in Eye Pressure Between Individuals. — 11.5; 11.3; 11.0; 11.0 mmHg — p=0.0001
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 4 N=99 Treating Disrupted Sleep in Individuals With Inflammatory Bowel Disease
Sleep Disturbance · Fatigue · Inflammatory Bowel Disease
Primary: Change From Baseline in Multidimensional Fatigue Inventory (MFI) for Each Arm — 18.727; -1.828; 16.367 units on a scale — p=<0.005
Phase 4 N=201 Efficacy Study of Articaine Versus Lidocaine as Supplemental Infiltration in Inflamed Molars
Irreversible Pulpitis
Primary: Anesthetic Success Rate of Supplemental Infiltration Injection — 22; 25; 23; 12 Participants — p=.901
Phase 4 N=1,077 Self-Administered Nasal Influenza Feasibility Study
Influenza
Primary: Post-vaccination Geometric Mean Titer (GMT) Ratios Between HCWA and SA Subjects — 45.8; 48.7; 45.5; 46.4 titer ratio — p=0.43
Phase 4 N=32 Glutamatergic and GABAergic Mediators of Antidepressant Response in Major Depression
MDD · Citalopram · Major Depressive Disorder
Primary: Mean Difference From Baseline to Day 3 in Glutamine/Glutamate (Gln/Glu) Ratio Within Depressed Group — 0.015 arbitrary units
Phase 4 N=101 Use of Dabigatran Etexilate to Prevent Stroke and Thromboembolism
Atrial Fibrillation · Atrial Flutter
Primary: Frequency of Major Bleeding Complications in Patients Administered Dabigatran Following RF Ablation. — 1 number of events
Phase 4 N=25 A Clinical Trial of Ambrisentan and Tadalafil in Pulmonary Arterial Hypertension Associated With Systemic Sclerosis
Pulmonary Arterial Hypertension · Systemic Sclerosis · Scleroderma Spectrum of Diseases
Primary: Right Ventricular (RV) Mass — 32.5; 28.0 grams
Phase 4 N=31 NAS Treatment - Opiate Versus Non-Opiate
Neonatal Abstinence Syndrome
Primary: Finnegan Neonatal Abstinence Scoring System — 7.5; 8.5; 6.6; 5.7 scores on a scale
Phase 4 N=59 Desvenlafaxine vs. Placebo Treatment of Chronic Depression
Dysthymic Disorder · Dysthymia · Chronic Depressive Disorder
Primary: Hamilton Rating Scale for Depression (HDRS24) — 14.63; 14.21 units on a scale — p=0.09
Phase 4 N=41 The Effect of Exenatide on Weight and Hunger in Obese, Healthy Women
Obesity · Impaired Glucose Tolerance
Primary: Change in Weight — -2.49; 0.43 kilograms
Phase 4 N=28 Investigating Veregen ™ 15% Ointment Treatment For Non-facial Verrucae in Pediatric Patients: A Pilot Study
Verruca, Warts
Primary: Size of Verrucae (Warts) — 2.333; 3.889 millimeters — p=0.383
Phase 4 N=383 3 Month Finasteride Challenge Test Can Significantly Improve the Performance of Screening for Prostate Cancer
Prostate Cancer
Primary: Pre/Post Ratio PSA Area Under the Curve (AUC) — 0.57; 0.61 Ratio
Phase 4 N=39 Safety and Tolerability of Rapid Dose Titration of Subcutaneous Remodulin® Therapy in PAH Subjects (RAPID)
Pulmonary Arterial Hypertension
Primary: Number of Participants With Successful Completion of the 16 Week Treatment Period. — 32 participants
Phase 4 N=155 Long Term Study of Avonex Therapy Following a First Attack of Multiple Sclerosis
Multiple Sclerosis · Optic Neuritis · Transverse Myelitis
Primary: Rate of Development of Clinical Definite Multiple Sclerosis (CDMS) Over 10 Years — 58; 69 Percent cumulative probability — p=0.001
Phase 4 N=1,107 Rapid Empiric Treatment With Oseltamivir Study (RETOS)
Influenza · Pneumonia
Primary: Number of Participants With Clinical Failure (Failure to Reach Clinical Stability) — 6; 2 Participants — p=.460